Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

DISEASE CHARACTERISTICS:

• Diagnosis of 1 of the following:
• Aplastic anemia not responsive to immunosuppressive therapy
• Metastatic renal cell carcinoma
• Hematologic malignancy, including any of the following:
• Acute myeloid leukemia (AML)* not curable with chemotherapy and meeting any of the following criteria:
• AML with high-risk cytogenetic abnormalities (e.g., -7, -7q, -5, -5q, complex, Philadelphia chromosome-positive [Ph+])
• AML evolved from prior myelodysplasia
• AML secondary to prior chemotherapy
• Failed to achieve remission
• In second or subsequent remission NOTE: *Marrow blasts < 10%- can be achieved by chemotherapy
• Myelodysplasia* with any of the following high-risk features:
• Adverse cytogenetics (-7, 7q, -5, -5q, complex)
• Excess blasts
• Prior conversion to AML
• Severe cytopenias with absolute neutrophil count < 500/mm^3 or platelet count < 20,000/mm^3 NOTE: *Marrow blasts < 10%- can be achieved by chemotherapy
• Acute lymphoblastic leukemia (ALL)* not curable with chemotherapy and meeting any of the following criteria:
• High-risk cytogenetics (Ph+, 11q23 abnormalities, monosomy 7)
• More than 1 induction course required to achieve remission
• Failed to enter remission
• In second or subsequent remission NOTE: *Marrow blasts < 10 %
• Chronic lymphocytic leukemia (CLL) with high-risk features, including any of the following:
• Refractory to initial or subsequent therapy
• Progression after initial response to therapy
• Prolymphocytic morphology
• Follicular lymphoma with any of the following high-risk features:
• Refractory to initial or subsequent therapy
• Progression after response to initial therapy
• Has ≥ 3 International Prognostic Index (IPI) risk factors
• Multiple myeloma
• Stage II-III disease confirmed at diagnosis or after initial progression
• Other lymphoma that has failed to respond to primary therapy, progressed, or recurred after prior therapy, including any of the following:
• Diffuse large cell lymphoma
• Mantle cell lymphoma
• Hodgkin's lymphoma
• Myeloproliferative disease with evidence of disease acceleration, including any of the following:
• Myelofibrosis
• Polycythemia vera
• Essential thrombocythemia
• Chronic myeloid leukemia (CML) that failed to be controlled by imatinib mesylate
• Disease must be stable or responding to therapy
• No rapid progression of malignant disease
• Expected time to disease progression > 12 weeks
• Not eligible for autologous stem cell transplantation
• Matched unrelated donor available
• 9/10 HLA matched, including HLA-A, -B, -C, -DR, and -DQ

PATIENT CHARACTERISTICS:

• Creatinine < 2.0 mg/dL
• Creatinine clearance > 40 mL/min
• Bilirubin < 3 mg/dL
• Elevated total bilirubin due to Gilbert's disease allowed if direct bilirubin is normal
• AST < 4 times upper limit of normal
• Hepatitis C or B allowed provided bilirubin and AST are normal
• Cardiac ejection fraction > 30%
• DLCO > 40% of predicted
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No uncontrolled active infection requiring ongoing antibiotic treatment
• No poor performance status
• No poor organ function

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• Prior stem cell or bone marrow transplantation allowed